• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)

    2/7/24 2:11:49 PM ET
    $TALS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TALS alert in real time by email
    SC 13G/A 1 trml13g020724.htm

    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

    SCHEDULE 13G*
    (Rule 13d-102)

    INFORMATION TO BE INCLUDED
    IN STATEMENTS FILED PURSUANT
    TO RULES 13d-1(b), (c), AND
    (d) AND AMENDMENTS THERETO
    FILED PURSUANT TO RULE 13d-2
    (AMENDMENT NO.  1   )*

    Tourmaline Bio, Inc.
    (Name of Issuer)
     
     Common stock, $0.0001 par value per share
    (Title of Class of Securities)
     
     89157D105
    (CUSIP Number)
     
     December 31, 2023
    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)
    ☒ Rule 13d-1(c)
    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

     
    1
    NAMES OF REPORTING PERSONS
     
     
     BML Investment Partners, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     245,500
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     245,500
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     245,500
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     1.0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     PN
     
     
     
     
     
    FOOTNOTES
       
      BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b)(1) of the Exchange Act.

    1
    NAMES OF REPORTING PERSONS
     
     
     Braden M Leonard
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     United States
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     245,500
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     245,500
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     245,500
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     1.0
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     IN
     
     
     
     

    Item 1(a). Name of Issuer:

     Tourmaline Bio, Inc.
     
    Item 1(b). Address of Issuer's Principal Executive Offices:

     
    27 West 24th Street, Suite 702
    New York, NY

    Item 2(a). Name of Person Filing:

     BML Investment Partners, L.P.

    Item 2(b). Address of Principal Business Office or, if none, Residence:

     65 E Cedar - Suite 2
    Zionsville, IN 46077

    Item 2(c). Citizenship:

    Delaware

    Item 2(d). Title of Class of Securities:

     Common stock, $0.0001 par value per share
     
    Item 2(e). CUSIP Number:

      89157D105


    Item 3. If This Statement Is Filed Pursuant to Sections 240.13d-1(b) or
    240.13d-2(b) or (c), Check Whether the Person Filing Is a(n):


    (a) ☐ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);


    (b) ☐ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);


    (c) ☐ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);


    (d) ☐ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);


    (e) ☐ Investment adviser in accordance with Section 240.13d-1(b)(1)(ii)(E);


    (f) ☐ Employee benefit plan or endowment fund in accordance with Section 240.13d-1(b)(1)(ii)(F);


    (g) ☐ Parent holding company or control person in accordance with Section 240.13d-1(b)(1)(ii)(G);


    (h) ☐ Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


    (i) ☐ Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


    (j) ☐ A non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J);


    (k) ☐ Group, in accordance with Section 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Section 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________________________ .
     
    Item 4. Ownership.


    (a) Amount beneficially owned: 245500


    (b) Percent of class: 1.0


    (c) Number of shares as to which the person has:


    (i) Sole power to vote or to direct the vote: 0


    (ii) Shared power to vote or to direct the vote: 245500

      (iii) Sole power to dispose or to direct the disposition of: 0

      (iv) Shared power to dispose or to direct the disposition of: 245500
     


    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.


     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Item 9. Notice of Dissolution of Group.

     
     
    Item 10.
    Certification.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Dated: February 7, 2024
     
     
    BML Capital Management, LLC
     
     
    By:
     /s/ Braden M Leonard
       
    Name:  Braden M Leonard
       
    Title:  Managing Member
     
     
     

    Get the next $TALS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TALS

    DatePrice TargetRatingAnalyst
    10/20/2022$18.00Buy
    H.C. Wainwright
    7/5/2022$20.00 → $8.00Overweight → Equal-Weight
    Morgan Stanley
    11/12/2021$21.00 → $22.00Outperform
    SVB Leerink
    More analyst ratings

    $TALS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

      Combined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, Inc. ("Tourmaline") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with a

      10/17/23 5:47:44 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

      Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp

      10/6/23 5:09:00 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

      NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe's Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the bi

      10/4/23 8:30:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    SEC Filings

    See more
    • Talaris Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits

      8-K - Tourmaline Bio, Inc. (0001827506) (Filer)

      1/26/24 4:12:52 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Talaris Therapeutics Inc.

      424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)

      1/26/24 4:08:02 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B5 filed by Talaris Therapeutics Inc.

      424B5 - Tourmaline Bio, Inc. (0001827506) (Filer)

      1/24/24 9:20:06 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      2/14/24 9:08:07 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Talaris Therapeutics Inc.

      SC 13G - Tourmaline Bio, Inc. (0001827506) (Subject)

      2/14/24 8:51:41 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Talaris Therapeutics Inc. (Amendment)

      SC 13G/A - Tourmaline Bio, Inc. (0001827506) (Subject)

      2/14/24 5:04:58 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Talaris Therapeutics with a new price target

      H.C. Wainwright initiated coverage of Talaris Therapeutics with a rating of Buy and set a new price target of $18.00

      10/20/22 7:24:56 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Talaris Therapeutics from Overweight to Equal-Weight and set a new price target of $8.00 from $20.00 previously

      7/5/22 7:28:16 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVB Leerink reiterated coverage on Talaris Therapeutics with a new price target

      SVB Leerink reiterated coverage of Talaris Therapeutics with a rating of Outperform and set a new price target of $22.00 from $21.00 previously

      11/12/21 9:44:40 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Leadership Updates

    Live Leadership Updates

    See more
    • Talaris Therapeutics Announces Leadership Transition

      BOSTON and LOUISVILLE, Ky., May 26, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), today announced the appointment of Mary Kay Fenton as interim Chief Executive Officer and President effective as of today. Ms. Fenton, who will continue as Talaris's Chief Financial Officer, succeeds Chief Executive Officer Scott Requadt who will be leaving the Company as part of a planned workforce reduction, as previously announced by the Company. "On behalf of the board, I would like to thank Scott for his unwavering commitment to patients and to Talaris over the past four and a half years," said Francois Nader, MD, Chairman of the Talaris Therapeutics Board of Directors. "I welcome M

      5/26/23 7:00:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics Announces Second Quarter Financial Results and Corporate Update

      All FREEDOM-1 patients who received FCR001 at least three months prior to the data cutoff date of June 15, 2022 had achieved and maintained >50% T-cell chimerism, and all three patients who were dosed at least 12 months post-transplant have discontinued their chronic anti-rejection drugs Multiple oral and poster presentations at the American Transplant Congress (ATC) 2022 highlighted key research findings and long-term Phase 2 follow up Strong cash balance with expected runway through 2024 BOSTON and LOUISVILLE, Ky., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform

      8/15/22 7:00:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics Announces Changes to Board of Directors

      BOSTON and LOUISVILLE, Ky., May 17, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced the appointment of independent director Karen Smith, M.D., Ph.D., MBA, LLM to the Company's Board of Directors. "Karen's long track record of developing and commercializing novel therapies and her wide-ranging industry experience make her a valuable addition to our Board of Directors," said Francois Nader, M.D., Chairman of the Board of Talaris. "I am pleased to welcome her to the team an

      5/17/22 7:00:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcdade Mark bought $3,250,000 worth of shares (100,000 units at $32.50) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/31/24 4:26:17 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Siegall Clay B

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      12/15/23 4:23:26 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Siegall Clay B

      3 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      12/15/23 4:21:42 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Mcdade Mark bought $3,250,000 worth of shares (100,000 units at $32.50) (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      1/31/24 4:26:17 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kulkarni Sandeep Chidambar bought $67,960 worth of shares (4,000 units at $16.99), increasing direct ownership by 0.55% to 729,735 units (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      11/20/23 6:15:47 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Thiara Parvinder bought $17,310 worth of shares (1,000 units at $17.31), increasing direct ownership by 1% to 83,782 units (SEC Form 4)

      4 - Tourmaline Bio, Inc. (0001827506) (Issuer)

      11/20/23 6:14:25 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TALS
    Financials

    Live finance-specific insights

    See more
    • Talaris Therapeutics Announces Stockholder Approval of Merger with Tourmaline Bio

      Combined Company to Trade on Nasdaq Under Ticker "TRML"Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") today announced the results of the special meeting of its stockholders held on October 17, 2023. At the special meeting, Talaris' stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Talaris' common stock to the stockholders of Tourmaline Bio, Inc. ("Tourmaline") pursuant to the terms of the Agreement and Plan of Merger, dated as of June 22, 2023, pursuant to which a direct wholly owned subsidiary of Talaris will merge with a

      10/17/23 5:47:44 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Talaris Therapeutics Declares Special Dividend In Connection with Proposed Merger with Tourmaline Bio

      Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris" or the "Company") today announced that its Board of Directors has declared a special dividend in connection with the previously announced merger (the "Merger") with Tourmaline Bio, Inc. ("Tourmaline") pursuant to the Agreement and Plan of Merger, dated June 22, 2023 (the "Merger Agreement"). The special dividend, which the Company estimates will be $1.5118 per share of Talaris common stock, will be payable in cash. The exact amount of the sp

      10/6/23 5:09:00 PM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New York Blood Center Enterprises Acquires Commercial-Scale Cell & Gene Therapy Development and Manufacturing Facilities from Talaris Therapeutics

      NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (NASDAQ:TALS) ("Talaris") announced today NYBCe's acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe's Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the bi

      10/4/23 8:30:00 AM ET
      $TALS
      Biotechnology: Pharmaceutical Preparations
      Health Care